Regulatory
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory landscapes. Get critical intelligence on FDA, EMA, and global drug approval pathways for strategic decision-making.
Showing 1–12 of 92 articles
Quick answer
NovaPharmaNews Regulatory hub for FDA covers 92 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA adds bemotrizinol to sunscreen rules, expanding U.S. UV filter options
Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
FDA Approves Lumasiran for PH1: What BD and Investors Should Know
Vabysmo gains EU approval for retinal vein occlusion: what changes next
Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services
Summit Pipeline Approvals and Competitive Outlook: 2023-2024 Update
Listeria Outbreak in Soft Cheese: FDA Investigation and Industry Impact
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
FDA Flavored Vape Ban: Youth Risk and Pharma Implications
Abivax colitis drug hits goal, but cancer cases rattle investors
STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.